1. Patients ≥18 years of age

          2. One of the following progressive advanced or metastatic cancers:

               1. Epithelial ovarian, fallopian tube, or primary peritoneal cancer (Part 1 and Part
                  2, Group 1 only) that is platinum refractory or platinum resistant

               2. Pancreatic adenocarcinoma (Part 1 and Part 2, Group 2 only) that is locally
                  advanced, and now with progressive disease on or after front-line treatment

               3. Malignant mesothelioma with epithelioid histology, pleural (Part 1 and Part 2,
                  Group 3 only) or primary peritoneal (Part 1 and Part 2, Group 3 only)

          3. For Part 2 only - Measurable disease according to RECIST v1.1 for patients with
             epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic
             adenocarcinoma, and peritoneal mesothelioma, and mRECIST v1.1 for patients with
             pleural mesothelioma

          4. Available archival tissue sample or fresh biopsy tissue sample must be obtained prior
             to enrollment

          5. For patients previously treated with systemic chemotherapy, targeted therapy,
             immunotherapy, or treatment with an investigational anticancer agent, discontinuation
             must have occurred ≥2 weeks, or at least 5 half-lives, whichever is longer, prior to
             start of study drug. The maximum washout period will not exceed 4 weeks

          6. ECOG performance status of 0 or 1

          7. Adequate bone marrow function, including:

               1. Absolute neutrophil count (ANC) ≥1500/mm3 or ≥1.5 x 109/L

               2. Platelets ≥100,000/mm3 or ≥100 x 109/L

               3. Hemoglobin (Hgb) ≥10 g/dL

          8. Adequate renal function, including estimated creatinine clearance ≥30 mL/min

          9. Adequate liver function, including:

               1. Total serum bilirubin ≤1.5 x upper limit of normal (ULN) unless the patient has
                  documented Gilbert syndrome in which case the maximum total serum bilirubin
                  should be <5 mg/dL

               2. Aspartate and alanine transaminase (AST and ALT) ≤2.5 x ULN or AST/ALT ≤5 x ULN
                  for patients with liver metastases

         10. Serum albumin as follows:

               1. ≥30 mg/mL for patients with epithelial ovarian cancer, fallopian tube cancer,
                  primary peritoneal cancer, or mesothelioma

               2. Within normal limits for patients with pancreatic adenocarcinoma

         11. Patients with pancreatic adenocarcinoma: C-reactive protein (CRP) within normal limits

        Key Exclusion Criteria:

          1. Previously treated or current brain metastases. Note: Patients with previously treated
             brain metastases may participate provided they are clinically stable for at least 4
             weeks prior to study entry and have no evidence of new or enlarging brain metastases

          2. Concurrent treatment with anti- TNFα therapies, systemic corticosteroids, or other
             immune suppressive drugs within the 2 weeks prior to Screening

          3. Patients with pancreatic adenocarcinoma: Any ascites within 1 month prior to screening

          4. History of or known or suspected autoimmune disease

          5. History of clinically significant cardiovascular disease

          6. Pulmonary, hematologic, renal, hepatic, gastrointestinal, neurological or psychiatric
             disease that would limit compliance with study requirements